세계의 항감염제 시장 : 제품별, 병원체별, 작용기작별, 투여 경로별, 최종 사용자별 예측(2025-2030년)

The Anti-infectives Market was valued at USD 125.78 billion in 2023, expected to reach USD 131.43 billion in 2024, and is projected to grow at a CAGR of 5.12%, to USD 178.43 billion by 2030.

The anti-infectives market encompasses a broad range of products designed to combat infections caused by bacteria, viruses, fungi, and parasites. This category includes antibiotics, antivirals, antifungals, and antiparasitic agents. The necessity of anti-infectives lies in their critical role in healthcare, as they are essential for treating infections, preventing disease spread, and reducing mortality. These agents find applications in hospitals, outpatient clinics, and home healthcare settings, catering to both human and veterinary needs. The market serves a wide demographic, from pediatric to geriatric populations, and supports numerous industries, including pharmaceuticals and biotechnology.

Market growth is primarily driven by factors such as the increasing prevalence of infectious diseases, growing awareness of antimicrobial resistance, and advances in drug development technologies. The rising need for new classes of anti-infectives, especially due to multidrug-resistant pathogens, presents significant opportunities. Companies can capitalize on these prospects by investing in R&D for novel therapeutics, exploring partnerships with biotechnology firms, and leveraging AI-driven drug discovery processes. Emerging economies also present lucrative markets due to their expanding healthcare infrastructure and rising healthcare expenditure.

However, the market faces several challenges, including stringent regulatory mandates and the high cost of R&D, which can hinder the pace of new drug development. Market players must also navigate the complexities of antimicrobial resistance, which requires continuous innovation and strategic investment. The best avenues for innovation include development of narrow-spectrum agents, combination therapies, and personalized anti-infective treatments tailored to individual genetic profiles.

In conclusion, while the anti-infectives market holds expansive potential, growth demands strategic focus on overcoming regulatory hurdles, improving cost efficiency, and fostering innovation. Pursuing collaborations with academic and research institutions can provide valuable insights and boost the development of groundbreaking solutions, positioning companies for sustainable growth in this dynamic market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-infectives Market

The Anti-infectives Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Expansion of healthcare infrastructure in emerging economies fueling the anti-infectives market growth
  • Stringent regulatory guidelines promoting the development and approval of effective anti-infective medications
  • The pharmaceutical industry's strategic collaborations and partnerships to boost anti-infective drug discovery
  • Increasing healthcare expenditure and better access to medical facilities driving demand for anti-infectives
• Market Restraints
  • Lower return on investment due to short product lifecycles and high cost of development in anti-infective market
  • Patient non-adherence to prescribed anti-infective regimens leading to suboptimal treatment outcomes and increased resistance
• Market Opportunities
  • Growth of personalized medicine approaches for targeted anti-infective treatments based on patient-specific factors
  • Leveraging artificial intelligence and machine learning for rapid identification of novel anti-infective compounds
  • Investing in advanced biotechnological research for development of next-generation anti-microbial therapies
• Market Challenges
  • Escalating research and development costs limiting innovation and new drug discoveries in anti-infectives
  • High market entry barriers preventing small and medium-sized enterprises from competing effectively

Porter's Five Forces: A Strategic Tool for Navigating the Anti-infectives Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-infectives Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-infectives Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-infectives Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-infectives Market

A detailed market share analysis in the Anti-infectives Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-infectives Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-infectives Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-infectives Market

A strategic analysis of the Anti-infectives Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-infectives Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Cubist Pharmaceuticals, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Shionogi & Co., Ltd., Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Anti-infectives Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Biologics, Drugs, and Vaccines. The Biologics is further studied across Interferons, Monoclonal Antibodies, and Recombinant Proteins. The Drugs is further studied across Intravenous, Oral Liquids, and Tablets. The Vaccines is further studied across Bacterial Vaccines and Viral Vaccines.
• Based on Pathogen, market is studied across Bacterial Infections, Fungal Infections, Parasitic Infections, and Viral Infections. The Bacterial Infections is further studied across Escherichia Coli and Staphylococcus Aureus. The Fungal Infections is further studied across Aspergillus and Candida. The Parasitic Infections is further studied across Leishmaniasis and Malaria. The Viral Infections is further studied across Hepatitis and HIV.
• Based on Mechanism Of Action, market is studied across Cell Wall Synthesis Inhibitors, Nucleic Acid Synthesis Inhibitors, and Protein Synthesis Inhibitors.
• Based on Route Of Administration, market is studied across Intravenous, Oral, and Topical.
• Based on End User, market is studied across Clinics, Homecare, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Expansion of healthcare infrastructure in emerging economies fueling the anti-infectives market growth
    • 5.1.1.2. Stringent regulatory guidelines promoting the development and approval of effective anti-infective medications
    • 5.1.1.3. The pharmaceutical industry's strategic collaborations and partnerships to boost anti-infective drug discovery
    • 5.1.1.4. Increasing healthcare expenditure and better access to medical facilities driving demand for anti-infectives
  • 5.1.2. Restraints
    • 5.1.2.1. Lower return on investment due to short product lifecycles and high cost of development in anti-infective market
    • 5.1.2.2. Patient non-adherence to prescribed anti-infective regimens leading to suboptimal treatment outcomes and increased resistance
  • 5.1.3. Opportunities
    • 5.1.3.1. Growth of personalized medicine approaches for targeted anti-infective treatments based on patient-specific factors
    • 5.1.3.2. Leveraging artificial intelligence and machine learning for rapid identification of novel anti-infective compounds
    • 5.1.3.3. Investing in advanced biotechnological research for development of next-generation anti-microbial therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Escalating research and development costs limiting innovation and new drug discoveries in anti-infectives
    • 5.1.4.2. High market entry barriers preventing small and medium-sized enterprises from competing effectively
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Anti-infectives Market, by Product

• 6.1. Introduction
• 6.2. Biologics
  • 6.2.1. Interferons
  • 6.2.2. Monoclonal Antibodies
  • 6.2.3. Recombinant Proteins
• 6.3. Drugs
  • 6.3.1. Intravenous
  • 6.3.2. Oral Liquids
  • 6.3.3. Tablets
• 6.4. Vaccines
  • 6.4.1. Bacterial Vaccines
  • 6.4.2. Viral Vaccines

7. Anti-infectives Market, by Pathogen

• 7.1. Introduction
• 7.2. Bacterial Infections
  • 7.2.1. Escherichia Coli
  • 7.2.2. Staphylococcus Aureus
• 7.3. Fungal Infections
  • 7.3.1. Aspergillus
  • 7.3.2. Candida
• 7.4. Parasitic Infections
  • 7.4.1. Leishmaniasis
  • 7.4.2. Malaria
• 7.5. Viral Infections
  • 7.5.1. Hepatitis
  • 7.5.2. HIV

8. Anti-infectives Market, by Mechanism Of Action

• 8.1. Introduction
• 8.2. Cell Wall Synthesis Inhibitors
• 8.3. Nucleic Acid Synthesis Inhibitors
• 8.4. Protein Synthesis Inhibitors

9. Anti-infectives Market, by Route Of Administration

• 9.1. Introduction
• 9.2. Intravenous
• 9.3. Oral
• 9.4. Topical

10. Anti-infectives Market, by End User

• 10.1. Introduction
• 10.2. Clinics
• 10.3. Homecare
• 10.4. Hospitals

11. Americas Anti-infectives Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Anti-infectives Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Anti-infectives Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Allergan plc
• 3. Amgen Inc.
• 4. Astellas Pharma Inc.
• 5. AstraZeneca PLC
• 6. Bayer AG
• 7. Bristol-Myers Squibb Company
• 8. Cubist Pharmaceuticals, Inc.
• 9. Eli Lilly and Company
• 10. F. Hoffmann-La Roche AG
• 11. Gilead Sciences, Inc.
• 12. GlaxoSmithKline plc
• 13. Johnson & Johnson
• 14. Merck & Co., Inc.
• 15. Novartis AG
• 16. Pfizer Inc.
• 17. Sanofi S.A.
• 18. Shionogi & Co., Ltd.
• 19. Takeda Pharmaceutical Company Limited
• 20. Vertex Pharmaceuticals Incorporated